259 related articles for article (PubMed ID: 32954611)
21. GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?
Field MG; Harbour JW
Cancer Cell; 2014 Jun; 25(6):714-5. PubMed ID: 24937456
[TBL] [Abstract][Full Text] [Related]
22. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
23. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Escape in Gαq-mutant Uveal Melanoma: It's a FAK.
Harbour JW
Clin Cancer Res; 2021 Jun; 27(11):2967-2969. PubMed ID: 33766812
[TBL] [Abstract][Full Text] [Related]
25. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.
Dono M; Angelini G; Cecconi M; Amaro A; Esposito AI; Mirisola V; Maric I; Lanza F; Nasciuti F; Viaggi S; Gualco M; Bandelloni R; Truini M; Coviello DA; Zupo S; Mosci C; Pfeffer U
Br J Cancer; 2014 Feb; 110(4):1058-65. PubMed ID: 24423917
[TBL] [Abstract][Full Text] [Related]
26. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
27. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.
Koopmans AE; Vaarwater J; Paridaens D; Naus NC; Kilic E; de Klein A;
Br J Cancer; 2013 Jul; 109(2):493-6. PubMed ID: 23778528
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
29. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
30. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
Daniels AB; Lee JE; MacConaill LE; Palescandolo E; Van Hummelen P; Adams SM; DeAngelis MM; Hahn WC; Gragoudas ES; Harbour JW; Garraway LA; Kim IK
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6991-6. PubMed ID: 22977135
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
32. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract][Full Text] [Related]
33. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
34. Driver mutations in
García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
[TBL] [Abstract][Full Text] [Related]
35. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
36. Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
Perez DE; Henle AM; Amsterdam A; Hagen HR; Lees JA
Pigment Cell Melanoma Res; 2018 Sep; 31(5):604-613. PubMed ID: 29570931
[TBL] [Abstract][Full Text] [Related]
37. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations.
Mudhar HS; Doherty R; Salawu A; Sisley K; Rennie IG
Br J Ophthalmol; 2013 Jul; 97(7):924-8. PubMed ID: 23685997
[TBL] [Abstract][Full Text] [Related]
39. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
40. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
